Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals
申请人:VEIJLEN N.V.
公开号:US10716778B2
公开(公告)日:2020-07-21
The present disclosure relates to the use of one or more compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition, in particular, in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome. The same composition can also be used by patients suffering from depression, Alzheimer disease, irritated bowel syndrome, osteoporosis, type 2 diabetes, or for anti-aging, immune therapy and recovery after exercise. The composition also has a use in veterinary applications for increasing the growth and immunity in animals.
本公开涉及一种或多种能够提高血清中胰岛素样生长因子1(IGF-1)水平的化合物用于制备治疗组合物,特别是以食品补充剂的形式,用于治疗患有严重疲劳和疲惫症状、倦怠和慢性疲劳综合征的患者。同样的组合物还可用于抑郁症、老年痴呆症、肠易激综合征、骨质疏松症、2 型糖尿病患者,或用于抗衰老、免疫疗法和运动后恢复。该成分还可用于兽医领域,提高动物的生长速度和免疫力。